Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1334 participants.

Also called NCT02389946

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,334 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02389946
Main results
  • Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial Lancet (London, England), 2017-10-21 DOI, PubMed 28851504 PubMed links an erratum for this paper. Erratum: PMID 28923464
Other papers using this trial's data
  • Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients Circulation. Cardiovascular interventions, 2018-10 DOI, PubMed 30354631
  • Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents Journal of the American College of Cardiology, 2018-12-25 DOI, PubMed 30257191
  • Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial JACC. Cardiovascular interventions, 2020-06-08 DOI, PubMed 32499026

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Canada, Denmark, Germany, Hungary, Israel, Netherlands, New Zealand, South Korea, Spain, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02389946. Randomized; single masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2017-04 (actual). Results posted on 2019-08-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
Acronym
BIOFLOW-V
Condition
Atherosclerosis, Coronary
Condition
Myocardial Ischemia
Condition
Ischemic Heart Disease
Condition
Acute Coronary Syndrome
Condition
Angina Pectoris
Intervention (Device)
Orsiro DES
Intervention (Device)
Xience DES
Lead sponsor
Biotronik, Inc. (class: industry)
Collaborator
Biotronik AG (class: industry)
Collaborator
Baim Institute for Clinical Research (class: other)
Collaborator
Medstar Health Research Institute (class: other)

Record details

Record id
cardio:ct-nct02389946
Content hash
a1254e491d3fe88679aff21e86043db11abb2e6aa252681085d075100369afdb